CSIRO link to heart failure prediction device
Melbourne based biotechnology company HD Medical Group Limited is moving rapidly towards international application of its world first, non-invasive heart failure prediction device, based on core technology licensed from the CSIRO ICT Centre.
The device, known as the ViScope(r), has the potential to revolutionise the early detection and management of heart diseases.
The HD Medical technology is based on mechanical heart sound analysis for early detection of cardiac diseases, a method which overcomes many of the limitations of current approaches which rely on echocardiography and stethoscopes.
The CSIRO has been working on non-contact vital signs research for a number of years leading to the appointment of HD Medical in late 2006.
Results from the Australian clinical trials are expected soon and a further clinical validation trial is planned.
